Gerilimzumab, a novel anti IL-6 antibody, has a unique pharmacokinetic profile with high potency and long half-life, which supports low and infrequent dosing and low cost of goods. IL-6 is a well-validated target for rheumatoid arthritis and has also been shown to be involved in inflammatory and autoimmune processes that lead to a number of diseases, including diabetes, Alzheimer’s disease, lupus, atherosclerosis (heart disease) and multiple types of cancers.
We believe gerilimzumab could be a best-in-class therapy with potentially deep pharmacoeconomic benefit. With low costs of goods and low and infrequent dosing, gerilimzumab could be priced for affordable access and still maintain a high gross margin. Developing gerilimzumab in emerging markets also provides a cost-effective clinical path.
Moderate to severe rheumatoid arthritis, inflammatory and autoimmune diseases.
Phase of Development
Gerilimzumab has completed Phase 1 clinical trials. Phase 2 is estimated to be initiated in the second half of 2016 in Brazil.